{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Rectal+Hypersensitivity", "query": { "condition": "Rectal Hypersensitivity" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 11, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Rectal+Hypersensitivity&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T01:50:41.406Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00584571", "title": "SAT vs Escitalopram for Rectal Hypersensitivity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rectal Hypersensitivity", "Irritable Bowel Syndrome-Constipation" ], "interventions": [ { "name": "Sensory Adaptation Training", "type": "PROCEDURE" }, { "name": "Escitalopram Therapy", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Augusta University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2007-12", "completion_date": "2019-12-31", "has_results": false, "last_update_posted_date": "2020-08-06", "last_synced_at": "2026-05-22T01:50:41.406Z", "location_count": 2, "location_summary": "Augusta, Georgia • Iowa City, Iowa", "locations": [ { "city": "Augusta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00584571" }, { "nct_id": "NCT07115875", "title": "Improving Rates of Diagnostic Colonoscopy in Native Americans", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "CRC Screening", "CRC (Colorectal Cancer)" ], "interventions": [ { "name": "Digital Outreach", "type": "OTHER" }, { "name": "In Person consultation", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Oklahoma", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "45 Years to 75 Years" }, "enrollment_count": 164, "start_date": "2025-12", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-09-30", "last_synced_at": "2026-05-22T01:50:41.406Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT07115875" }, { "nct_id": "NCT00305643", "title": "Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer", "Colorectal Cancer", "Pain" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "PROCEDURE" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2006-02", "completion_date": "2008-10", "has_results": true, "last_update_posted_date": "2015-12-24", "last_synced_at": "2026-05-22T01:50:41.406Z", "location_count": 13, "location_summary": "Santa Rosa, California • Grand Rapids, Michigan • Kalamazoo, Michigan + 10 more", "locations": [ { "city": "Santa Rosa", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Kalamazoo", "state": "Michigan" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Springfield", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00305643" }, { "nct_id": "NCT04506593", "title": "Indiana University Gastrointestinal Motility Diagnosis Registry", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Eosinophilic Esophagitis", "Gastroesophageal Reflux Disease (GERD)", "Gastroparesis", "Functional Vomiting", "Irritable Bowel Syndrome (IBS)", "Constipation", "Chronic Intestinal Pseudo-obstruction", "Fecal Incontinence", "Small Intestinal Bacterial Overgrowth" ], "interventions": [ { "name": "no intervention", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 5000, "start_date": "2014-11", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2024-08-15", "last_synced_at": "2026-05-22T01:50:41.406Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04506593" }, { "nct_id": "NCT04171700", "title": "A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "Rucaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "pharmaand GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2020-01-16", "completion_date": "2022-07-15", "has_results": true, "last_update_posted_date": "2023-10-02", "last_synced_at": "2026-05-22T01:50:41.406Z", "location_count": 19, "location_summary": "Los Angeles, California • San Francisco, California • Fort Myers, Florida + 15 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04171700" }, { "nct_id": "NCT03190174", "title": "Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ewing Sarcoma", "PEComa", "Epithelioid Sarcoma", "Desmoid Tumor", "Chordoma", "Non Small Cell Lung Cancer", "Urothelial Carcinoma", "Melanoma", "Renal Cell Carcinoma", "Squamous Cell Carcinoma", "Hepatocellular Carcinoma", "Classical Hodgkin Lymphoma", "Colorectal Cancer", "MTOR Activating Mutation" ], "interventions": [ { "name": "Nab-Rapamycin", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Sarcoma Oncology Research Center, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 34, "start_date": "2017-08-24", "completion_date": "2021-12-02", "has_results": true, "last_update_posted_date": "2025-02-17", "last_synced_at": "2026-05-22T01:50:41.406Z", "location_count": 1, "location_summary": "Santa Monica, California", "locations": [ { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03190174" }, { "nct_id": "NCT07209215", "title": "ctDNA-Informed Management of Early-Stage Rectal Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rectal Adenocarcinoma", "Rectal Cancer", "Early-stage Rectal Cancer", "Locally Advanced Rectal Adenocarcinoma" ], "interventions": [ { "name": "Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy (TNT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2026-03", "completion_date": "2028-05", "has_results": false, "last_update_posted_date": "2026-01-20", "last_synced_at": "2026-05-22T01:50:41.406Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07209215" }, { "nct_id": "NCT01931644", "title": "At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "All Diagnosed Health Conditions", "ADD/ADHD", "Alopecia Areata", "Ankylosing Spondylitis", "Asthma", "Atopic Dermatitis Eczema", "Beta Thalassemia", "Bipolar Disorder", "Breast Cancer", "Celiac Disease", "Cervical Cancer", "Chronic Inflammatory Demyelinating Polyneuropathy", "Chronic Kidney Diseases", "Chronic Obstructive Pulmonary Disease", "Colon Cancer", "Colorectal Cancer", "Crohn's Disease", "Cystic Fibrosis", "Depression", "Diabetes Mellitus", "Duchenne Muscular Dystrophy", "Endometriosis", "Epilepsy", "Facioscapulohumeral Muscular Dystrophy", "G6PD Deficiency", "General Anxiety Disorder", "Hepatitis B", "Hereditary Hemorrhagic Telangiectasia", "HIV/AIDS", "Human Papilloma Virus", "Huntington's Disease", "Idiopathic Thrombocytopenic Purpura", "Insomnia", "Kidney Cancer", "Leukemia", "Lung Cancer", "Lupus Nephritis", "Lymphoma", "Melanoma", "Multiple Myeloma", "Multiple Sclerosis", "Myositis", "Myotonic Dystrophy", "Ovarian Cancer", "Pancreatic Cancer", "Parkinson's Disease", "Polycystic Kidney Diseases", "Prostate Cancer", "Psoriasis", "Psoriatic Arthritis", "Rosacea", "Scleroderma", "Sickle Cell Anemia", "Sickle Cell Trait", "Sjogren's Syndrome", "Skin Cancer", "Spinal Muscular Atrophy", "Systemic Lupus Erythematosus", "Thrombotic Thrombocytopenic Purpura", "Trisomy 21", "Ulcerative Colitis" ], "interventions": [], "intervention_types": [], "sponsor": "Sanguine Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 17667, "start_date": "2013-07", "completion_date": "2024-04", "has_results": false, "last_update_posted_date": "2024-04-18", "last_synced_at": "2026-05-22T01:50:41.406Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01931644" }, { "nct_id": "NCT00831571", "title": "Prospective Analysis of Hypersensitivity Reactions to Oxaliplatin", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Colorectal Cancer", "Esophageal Cancer", "Gastric Cancer", "Small Bowel Cancer", "Pancreatic Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 112, "start_date": "2009-02", "completion_date": "2022-04", "has_results": false, "last_update_posted_date": "2022-04-18", "last_synced_at": "2026-05-22T01:50:41.406Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00831571" }, { "nct_id": "NCT03254394", "title": "Lidocaine for Oxaliplatin-induced Neuropathy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neuropathy, Painful", "Chemotherapy-induced Peripheral Neuropathy", "Colorectal Cancer" ], "interventions": [ { "name": "Lidocaine Hydrochloride", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "FOLFOX regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2017-09-15", "completion_date": "2021-04-01", "has_results": true, "last_update_posted_date": "2022-03-09", "last_synced_at": "2026-05-22T01:50:41.406Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03254394" } ] }